News on Medial

Biotech startup Exsure raises seed round led by Unicorn India Ventures

Entrackr · 6h

Biotech startup Exsure has raised Rs 3 crore in a seed round led by Unicorn India Ventures. The fresh funds will be used to complete the non-clinical study of its exosome-based drug delivery platform, support its global expansion plans with in-house manufactured R&D products, and promote its offerings, including Exosure, Leucosure, PlantExosure, and Dr. Berries, the company said in a press release. Co-founded in 2021 by Swastika Paul and Abhishek Dutta, Exsure is a biotech startup focused on reducing the side effects and toxicity of anti-cancer drugs through its patented exosomal drug-delivery platform that targets both cancer and cancer stem cells. With its cutting-edge technology, the company aims to minimize the toxic effects of chemotherapy and reduce the likelihood of cancer relapse, thereby improving the quality of life for cancer patients. Over the past 12 months, Exsure has initiated a non-clinical study in India in collaboration with a CRO and completed preclinical studies using its patented technology. The company has launched its first in-house manufactured products and gained collaborators and partners across India for its products and services. According to market research, the Indian biotechnology industry is expected to reach $150 billion by 2025 and has the potential to grow to $270–300 billion by 2030. The Bhubaneswar-based company reported fivefold growth in the last fiscal year and is on track to service more than 50 clients this year with its R&D products, including Exosure (a 3-in-1 exosome isolation reagent), Leucosure (a PBMC isolation reagent), and PlantExosure (India’s first plant exosome isolation reagent). Additionally, the company has been selected for the OIST Innovation Accelerator Program in Japan to support its business expansion and conduct clinical trials.